Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214870) titled 'A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat' on Oct. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novo Nordisk A/S
Condition:
Fatty Liver Disease
Intervention:
Drug: NNC4005-001
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 7, 2025
Target Sample Size: 60
Countries of Recruitment:...